Janus-activated kinase 2 inhibitors: A new era of targeted therapies providing significant clinical benefit for philadelphia chromosome-negative myeloproliferative neoplasms

Srdan Verstovsek

Research output: Contribution to journalEditorialpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)781-783
Number of pages3
JournalJournal of Clinical Oncology
Volume29
Issue number7
DOIs
StatePublished - Mar 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this